Revision as of 07:16, 1 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to watched fields - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit | Latest revision as of 10:59, 28 December 2023 edit undoMRTFR55 (talk | contribs)Extended confirmed users2,453 edits Rescuing 3 sources and tagging 0 as dead.) #IABot (v2.0.9.5Tag: IABotManagementConsole [1.3] | ||
(27 intermediate revisions by 19 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Cough suppressant}} | |||
{{Drugbox | {{Drugbox | ||
| |
| Verifiedfields = changed | ||
| verifiedrevid = |
| verifiedrevid = 447812881 | ||
| IUPAC_name = N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine | | IUPAC_name = N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine | ||
| image = Oxolamine.png | | image = Oxolamine.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = |
| tradename = | ||
| Drugs.com = {{drugs.com|international|oxolamine}} | | Drugs.com = {{drugs.com|international|oxolamine}} | ||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | ||
| pregnancy_US = <!-- A / B / C / D / X --> | | pregnancy_US = <!-- A / B / C / D / X --> | ||
| pregnancy_category = |
| pregnancy_category = | ||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | ||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | ||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | ||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | ||
| legal_status = |
| legal_status = | ||
| routes_of_administration = |
| routes_of_administration = | ||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = |
| bioavailability = | ||
| protein_bound = |
| protein_bound = | ||
| metabolism = |
| metabolism = | ||
| elimination_half-life = |
| elimination_half-life = | ||
| excretion = |
| excretion = | ||
<!--Identifiers--> | <!--Identifiers--> | ||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 959-14-8 | | CAS_number = 959-14-8 | ||
| ATC_prefix = R05 | | ATC_prefix = R05 | ||
Line 31: | Line 33: | ||
| PubChem = 13738 | | PubChem = 13738 | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| DrugBank = |
| DrugBank = DB13216 | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| ChemSpiderID = 13143 | | ChemSpiderID = 13143 | ||
Line 38: | Line 40: | ||
| KEGG_Ref = {{keggcite|correct|kegg}} | | KEGG_Ref = {{keggcite|correct|kegg}} | ||
| KEGG = D07387 | | KEGG = D07387 | ||
| ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| ChEMBL = 1620875 | |||
<!--Chemical data--> | <!--Chemical data--> | ||
| C=14 | H=19 | N=3 | O=1 |
| C=14 | H=19 | N=3 | O=1 | ||
| molecular_weight = 245.32 g/mol | |||
| smiles = n1c(onc1c2ccccc2)CCN(CC)CC | | smiles = n1c(onc1c2ccccc2)CCN(CC)CC | ||
| InChI = 1/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3 | |||
| InChIKey = IDCHQQSVJAAUQQ-UHFFFAOYAF | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| StdInChI = 1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3 | | StdInChI = 1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3 | ||
Line 51: | Line 52: | ||
}} | }} | ||
'''Oxolamine''' is a ]<ref>{{cite book | vauthors = de Groot AC | chapter = 3.357 Oxolamine |title=Systemic Drugs | series = Monographs in Contact Allergy | volume = 4 |date=2022 |publisher=CRC Press |isbn=978-1-00-054991-1 |page=712 |edition=First}}</ref> that is available as a ] in many jurisdictions.<ref>{{cite web | work = drugs.com | url = https://www.drugs.com/international/oxolamine.html | title = Oxolamine | date = 19 April 2015 | access-date = 23 January 2018 | archive-date = 20 September 2018 | archive-url = https://web.archive.org/web/20180920145016/https://www.drugs.com/international/oxolamine.html | url-status = live }}</ref> | |||
'''Oxolamine''' is a ]. | |||
Oxolamine also has ] activity, which causes a reduction in irritation of the nerve receptors of the ].<ref name=":0">{{Cite web |title=NCATS Inxight Drugs — OXOLAMINE CITRATE |url=https://drugs.ncats.io/drug/K5X4XBR694 |access-date=2022-09-26 |website=drugs.ncats.io |language=en |archive-date=2022-09-26 |archive-url=https://web.archive.org/web/20220926180401/https://drugs.ncats.io/drug/K5X4XBR694 |url-status=live }}</ref> | |||
==Synthesis== | |||
The syntheses of 1,2,4-] systems all rely on ] for providing a preformed N-O linkage. The preparation of the respiratory anti-inflammatory and antitussive agent oxolamine starts by ] of the ] from the N-hydroxyamidine with 3-chloropropionyl chloride; the presence of the negative charge on oxygen results in the formation of the O-acylated product. Treatment of that intermediate with ] leads | |||
to cyclization via imine formation to afford the 1,2,4-oxadiazole. Displacement of the terminal ] with ] gives the corresponding amine oxolamine. | |||
It is mainly used for the treatment of ], ], ], bronchiectasis and ].<ref name=":0" /> | |||
] | |||
Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant. It is listed as a ] in New Zealand legislation. Oxolamine is also approved in Taiwan for the treatment of ].<ref>{{Cite web |title=Oxolamine |url=https://go.drugbank.com/drugs/DB13216 |access-date=2022-09-26 |website=go.drugbank.com |archive-date=2022-09-26 |archive-url=https://web.archive.org/web/20220926180403/https://go.drugbank.com/drugs/DB13216 |url-status=live }}</ref> | |||
{{Cite patent|DE|1097998}} | |||
==References== | |||
{{reflist}} | |||
{{Cough and cold preparations}} | {{Cough and cold preparations}} | ||
Line 65: | Line 67: | ||
] | ] | ||
] | ] | ||
] | ] | ||
{{respiratory-system-drug-stub}} |
Latest revision as of 10:59, 28 December 2023
Cough suppressant Pharmaceutical compoundClinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.012.267 |
Chemical and physical data | |
Formula | C14H19N3O |
Molar mass | 245.326 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Oxolamine is a cough suppressant that is available as a generic drug in many jurisdictions.
Oxolamine also has anti-inflammatory activity, which causes a reduction in irritation of the nerve receptors of the respiratory tract.
It is mainly used for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis and pertussis.
Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant. It is listed as a prescription drug in New Zealand legislation. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflammation.
References
- de Groot AC (2022). "3.357 Oxolamine". Systemic Drugs. Monographs in Contact Allergy. Vol. 4 (First ed.). CRC Press. p. 712. ISBN 978-1-00-054991-1.
- "Oxolamine". drugs.com. 19 April 2015. Archived from the original on 20 September 2018. Retrieved 23 January 2018.
- ^ "NCATS Inxight Drugs — OXOLAMINE CITRATE". drugs.ncats.io. Archived from the original on 2022-09-26. Retrieved 2022-09-26.
- "Oxolamine". go.drugbank.com. Archived from the original on 2022-09-26. Retrieved 2022-09-26.
This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it. |